These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 9922042

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia.
    Pratz KW, Rudek MA, Gojo I, Litzow MR, McDevitt MA, Ji J, Karnitz LM, Herman JG, Kinders RJ, Smith BD, Gore SD, Carraway HE, Showel MM, Gladstone DE, Levis MJ, Tsai HL, Rosner G, Chen A, Kaufmann SH, Karp JE.
    Clin Cancer Res; 2017 Feb 15; 23(4):899-907. PubMed ID: 27551000
    [Abstract] [Full Text] [Related]

  • 24. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.
    Alfonso A, Montalban-Bravo G, Takahashi K, Jabbour EJ, Kadia T, Ravandi F, Cortes J, Estrov Z, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos C, Pierce S, Kantarjian H, Garcia-Manero G.
    Am J Hematol; 2017 Jul 15; 92(7):599-606. PubMed ID: 28370097
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.
    Santini V, Allione B, Zini G, Gioia D, Lunghi M, Poloni A, Cilloni D, Sanna A, Masiera E, Ceccarelli M, Abdel-Wahab O, Terenzi A, Angelucci E, Finelli C, Onida F, Pelizzari A, Ferrero D, Saglio G, Figueroa M, Levis A.
    Leukemia; 2018 Feb 15; 32(2):413-418. PubMed ID: 28607470
    [Abstract] [Full Text] [Related]

  • 27. Results of chromosome studies and their relation to morphology, course, and prognosis in 120 patients with de novo myelodysplastic syndrome.
    Suciu S, Kuse R, Weh HJ, Hossfeld DK.
    Cancer Genet Cytogenet; 1990 Jan 15; 44(1):15-26. PubMed ID: 2293879
    [Abstract] [Full Text] [Related]

  • 28. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML).
    Wijermans PW, Rüter B, Baer MR, Slack JL, Saba HI, Lübbert M.
    Leuk Res; 2008 Apr 15; 32(4):587-91. PubMed ID: 17881052
    [Abstract] [Full Text] [Related]

  • 29. Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndromes.
    Raza A, Lisak L, Billmeier J, Pervaiz H, Mumtaz M, Gohar S, Wahid K, Galili N.
    Leuk Lymphoma; 2006 Mar 15; 47(3):433-40. PubMed ID: 16396766
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group.
    Hochster H, Wadler S, Runowicz C, Liebes L, Cohen H, Wallach R, Sorich J, Taubes B, Speyer J.
    J Clin Oncol; 1999 Aug 15; 17(8):2553-61. PubMed ID: 10561322
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).
    de Witte T, Suciu S, Peetermans M, Fenaux P, Strijckmans P, Hayat M, Jaksic B, Selleslag D, Zittoun R, Dardenne M.
    Leukemia; 1995 Nov 15; 9(11):1805-11. PubMed ID: 7475266
    [Abstract] [Full Text] [Related]

  • 34. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
    Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP.
    Blood; 2007 Jan 01; 109(1):52-7. PubMed ID: 16882708
    [Abstract] [Full Text] [Related]

  • 35. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group.
    Wattel E, Guerci A, Hecquet B, Economopoulos T, Copplestone A, Mahé B, Couteaux ME, Resegotti L, Voglova V, Foussard C, Pegourié B, Michaux JL, Deconinck E, Stoppa AM, Mufti G, Oscier D, Fenaux P.
    Blood; 1996 Oct 01; 88(7):2480-7. PubMed ID: 8839839
    [Abstract] [Full Text] [Related]

  • 36. Thalidomide for the treatment of patients with myelodysplastic syndromes.
    Strupp C, Germing U, Aivado M, Misgeld E, Haas R, Gattermann N.
    Leukemia; 2002 Jan 01; 16(1):1-6. PubMed ID: 11840256
    [Abstract] [Full Text] [Related]

  • 37. A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia.
    Rowinsky EK, Kaufmann SH, Baker SD, Miller CB, Sartorius SE, Bowling MK, Chen TL, Donehower RC, Gore SD.
    Clin Cancer Res; 1996 Dec 01; 2(12):1921-30. PubMed ID: 9816150
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
    Wu L, Li X, Su J, Chang C, He Q, Zhang X, Xu L, Song L, Pu Q.
    Leuk Lymphoma; 2009 Sep 01; 50(9):1461-7. PubMed ID: 19672772
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.